Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

haemodialysis

- PMLiVE

Ionis shares positive late-stage results for olezarsen in familial chylomicronaemia syndrome

The rare genetic disease is estimated to affect up to 13 people per million in the US

- PMLiVE

Ionis shares positive phase 3 results for hereditary angioedema drug candidate

More than 20,000 people in the US and Europe are affected by the rare genetic disease

- PMLiVE

Ionis reports positive phase 2b results for fesomersen in thrombosis prevention

The company also announced it will regain rights to the antisense medicine from Bayer

- PMLiVE

Merck granted fast track designation by FDA for end-stage renal disease therapy

MK-2060 is currently being investigated in a phase 2 study to evaluate the efficacy and safety of two different doses

- PMLiVE

AstraZeneca and Ionis sign $3.6bn deal for eplontersen

The liver-targeted antisense therapy is in phase 3 trials for the treatment of transthyretin amyloidosis, a systemic, progressive and fatal condition

- PMLiVE

GSK’s Ionis-partnered hepatitis B drug hits the mark in phase 2

Treatment could be transformative for around 260 million people living with disease

- PMLiVE

Quality in Care anticoagulation programme open for entry

PMGroup's QiC programme aims to recognise best practice in care in the UK

- PMLiVE

Pharma supports first World Thrombosis Day

Aims to raise awareness of the blood clot condition

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links